Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Takayasu arteritis - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

Takayasu arteritis

MONDO:0017991

Also known as:Arteritis, TakayasuTakayasu's arteritisTakayasu's disease

Find Clinical TrialsTrials

Overview

A rare inflammatory large-vessel vasculitis primarily affecting the aorta and its major branches, but also other large vessels, causing stenosis, occlusion, or aneurysm.

GeneticsAutosomal recessive

TreatmentsNo approved treatments · 2 in pipeline

Clinical Trials32 registered · 19 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Arteritis, Abnormal heart valve (abnormal heart valve morphology), Weight loss, and Fever and others; and common findings: Hypertension, Seizure, Muscle weakness, and Joint inflammation (arthritis) and others. 54 total HPO annotations.

Organ System	Phenotype Count	Example Features
Heart and blood vessels	13	Abnormal heart valve (abnormal heart valve morphology), Hypertensive crisis, Hypertension

Diagnosis

Biomarker and diagnostic research for Takayasu arteritis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for Takayasu arteritis. An additional 2 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for Takayasu arteritis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for Takayasu arteritis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Phenotype severity distribution: 9 very common features, 24 common features.

Estimated prevalence: 1-9 in 100,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

32 clinical trials registered, 19 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and biologic therapy. Pipeline includes 7 PHASE4, 1 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT02967068](https://clinicaltrials.gov/study/NCT02967068)

Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 8:57 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:207600

Orphanet

European rare disease database

Orphanet:3287 Orphanet:99079

GARD

Genetic and Rare Diseases Info Center

GARD:7730

Questions for Your Care Team

→Should my partner and I meet with a genetic counselor to discuss carrier status and family planning?
→Are any of the 32 active clinical trials a good fit for my situation?
→What is the current development status of tocilizumab, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	54	25%
Patient case studies	42	19%
Disease patterns and progression	42	19%
Clinical study results	26	12%
Testing and diagnosis research	25	11%
Laboratory research	23	10%
Other research	8	4%

Kisho

Takayasu arteritis

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

"Severe Aortic Regurgitation as the Initial Manifestation of Takayasu Arteritis in a Young Woman: A Case Report".

Refractory Kawasaki Disease in Infants Complicated with Giant Coronary Artery Aneurysms and Takayasu Arteritis: A Rare Case Report and Literature Review.

Childhood-Onset Takayasu Arteritis With Extensive Vascular Involvement: A Four-Decade Follow-Up Case Report.

Takayasu arteritis

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

"Severe Aortic Regurgitation as the Initial Manifestation of Takayasu Arteritis in a Young Woman: A Case Report".

Refractory Kawasaki Disease in Infants Complicated with Giant Coronary Artery Aneurysms and Takayasu Arteritis: A Rare Case Report and Literature Review.

Childhood-Onset Takayasu Arteritis With Extensive Vascular Involvement: A Four-Decade Follow-Up Case Report.